Female Patient with Ceftriaxone-Induced Drug Eruption with Eosinophilia and Systemic Symptoms in Second Level Care. Case Report

Main Article Content

Dora Patricia Ortega García
Estanislao Antonio Calixto
Cindy Y. Bedolla Rosales
Roberto Lazcano Dueñas
Hamayraky Hernández González

Abstract

Drug reaction with eosinophilia and systemic symptoms (DRESS) is a hypersensitivity reaction. Therefore, the case of a 51-year-old woman with no history of drug allergies is presented. In empirical treatment with Ceftriaxone, presenting 15 days later pruritic maculopapular rash on the chest, abdomen and extremities accompanied by temperature rises of up to 39°C. Laboratories with leukocytes of 47.38/uL, with eosinophils of 27.07/uL, and skin biopsy report with inflammatory infiltrate in the dermis at the expense of eosinophils. regiSCAR and J-SCAR with results of 8 and 6 points respectively. Administering methylprednisolone 250 mg every 24 hours for 3 days, continuing with prednisone 50 mg per day. Improvement of skin lesions and laboratory abnormalities at 72 hours. DRESS induced by this antibiotic is rare. Appropriate assessment of the indications and diagnostic assumption of side effects is important because the manifestations are potentially reversible.of rash, fever, facial edema, lymphadenopathy, hematologic abnormalities, and visceral involvement.

Article Details

How to Cite
Ortega García, D. P. . ., Antonio Calixto, E., Bedolla Rosales, C. Y., Lazcano Dueñas, R. ., & Hernández González, H. . (2022). Female Patient with Ceftriaxone-Induced Drug Eruption with Eosinophilia and Systemic Symptoms in Second Level Care. Case Report. International Journal of Medical Science and Clinical Research Studies, 2(10), 1183–1185. https://doi.org/10.47191/ijmscrs/v2-i10-32
Section
Articles
Author Biographies

Cindy Y. Bedolla Rosales, Department of Internal Medicine. Hospital of High Specialty of Veracruz SESVER. Veracruz Mexico.

Department of Internal Medicine. Regional Hospital of High Specialty of Veracruz SESVER. Veracruz Mexico.

Roberto Lazcano Dueñas, Department of Internal Medicine. Hospital of High Specialty of Veracruz SESVER. Veracruz Mexico.

Department of Internal Medicine. Regional Hospital of High Specialty of Veracruz SESVER. Veracruz Mexico.

Hamayraky Hernández González, Department of Internal Medicine. Hospital of High Specialty of Veracruz SESVER. Veracruz Mexico.

Department of Internal Medicine. Regional Hospital of High Specialty of Veracruz SESVER. Veracruz Mexico.

References

I. Stirton H, Shear NH, Gad RPD. Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS)/Drug-Induced Hypersensitivity Syndrome (DiHS)—Readdressing the DReSS. Biomedicines 2022, 10, 999.

II. Shiohara T, Mizukawa Y. Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019. Allergology International 68 (2019) 301-308.

III. NamY.H,ParkMR,NamHJ,LeeSK,KimKH, et al. Drug reaction with eosinophilia and systemic symptoms syndrome is not uncommon and shows better clinical outcome than generally recognized. Allergol Immunopathol (Madr). 2 01 5; 43 (1) :1 9- 2 4.

IV. Sharifzadeh S, Mohammadpour AH, Tavanae A, Elyasi S. Antibacterial antibiotic-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a literature review. European Journal of Clinical Pharmacology (2021) 77:275–289.

V. Da silva SA, Figuereido MP, Neto LC, Reiis DB, Damásio MS. Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome). Rev assoc med BRas 2016; 62(3):227-230.

VI. Cardones AR. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. Clinics in Dermatology (2020) 38, 702–711.

VII. Agrawal A, Ravindu, Kannauje P. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by ceftriaxone with successful treatment — A case report and literature review. ndian Journal of Pharmacy and Pharmacology 2021;8(4):298–300.

VIII. Cho YT, Yang CW, Chu CY. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): An Interplay among Drugs, Viruses, and Immune System. Int. J. Mol. Sci. 2017, 18, 1243.

IX. Scrace B, Fityan A, Bigham C. Drug reactions with eosinophilia and systemic symptoms. BJA Education, 20(2): 65e71 (2020).

X. Guleria VS, Dhillon M, Gill S, Naithani N. Ceftriaxone induced drug rash with eosinophilia and systemic symptoms. J Res Pharm Pract 2014;3:72‐4.

XI. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome. J AM ACAD DERMATOL MAY 2013. VOLUME 68, NUMBER 5.

XII. Criado PR, Jardim CRF, Avancini MJ, Giuli SC, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) / Drug-Induced Hypersensitivity Syndrome (DIHS): An Bras Dermatol. 2012;87(3):435-49.

Most read articles by the same author(s)

<< < 1 2